Pharmacologic treatment of stress urinary incontinence: expectations for outcome.
Several classes of drugs have been investigated for their efficacy in treating stress urinary incontinence (SUI). Despite targeting the mechanisms known to be involved in maintaining continence, few have provided the desired benefits without causing significant adverse effects. Duloxetine, the newest drug to be extensively evaluated for SUI treatment, appears to be both safe and effective. None of the drugs tested thus far has proved to be curative, however. Treatment strategies therefore are aimed at improving the quality of life of patients and should take into account their individual needs and preferences.
Schuessler
Bernhard
B
Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Lucerne, Switzerland. schuessler@tic.ch
Baessler
Kaven
K
D000293:Adolescent; D018663:Adrenergic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D000068736:Duloxetine Hydrochloride; D004967:Estrogens / Q000627:therapeutic use; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D017060:Patient Satisfaction; D017773:Pelvic Floor / Q000503:physiopathology; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery / Q000628:therapy
D018663:Adrenergic Agents; D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D004967:Estrogens; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes